Recent events
Recent events tied to this brand in public sources.
Back to profile13 entries
2026
XtalPi announces collaboration with MARVEL-AI
XtalPi announced a collaboration with MARVEL-AI, led by Singapore's A*STAR, to contribute AI, computational prediction, robotic experimentation and experimental feedback capabilities to advance materials discovery and industrial translation.
2026
XtalPi Holdings releases 2026 interim results
XtalPi Holdings reported 2026 first-half revenue of RMB 393.6 million, down from RMB 517.1 million a year earlier, mainly due to a high base from a USD 51.0 million upfront licensing payment recognized in the prior-year period; excluding that effect, revenue grew 73.8% year on year. The group reported a net loss of RMB 224.9 million and an adjusted net loss of RMB 105.5 million, with R&D expenses up 66.0% year on year, and held cash of RMB 8,671.2 million as of June 30, 2026.
2026
XtalPi appoints Maria G. Belvisi as Chief Scientific Officer
XtalPi Holdings appointed Dr. Maria G. Belvisi as Chief Scientific Officer. Belvisi has over 30 years of drug discovery and academic leadership experience, including about ten years at AstraZeneca where she served as Senior Vice President of Respiratory and Immunology in biopharmaceuticals R&D.
2026
XtalPi and Dongyangguang Pharmaceutical sign strategic cooperation to form joint venture
XtalPi Holdings signed a strategic cooperation agreement with Dongyangguang Pharmaceutical; the two parties plan to establish a joint venture company and jointly build an AI plus robotics joint laboratory and a non-clinical drug large model, carrying out cooperation on underlying technology, new drug pipeline development and commercialization. Dongyangguang Pharmaceutical is expected to invest several hundred million yuan, with the two companies aiming to build an industry-leading AI drug R&D engine and achieve technology going global.
2026
XtalPi signs AI drug discovery strategic partnership worth over USD 400 million
XtalPi Holdings reached an AI drug discovery strategic partnership with an internationally known biopharmaceutical company with a rich pipeline and multiple commercialized products, with a potential total value of over USD 400 million. The two parties will jointly develop a Best-in-Class potential oral small molecule drug against a GPCR target; the partner will pay an upfront payment and bear all early R&D costs, while XtalPi will also receive preclinical, clinical and commercialization milestone payments and future sales royalties.
2026
XtalPi signs AI plus automation high-throughput tandem solar cell R&D strategic cooperation with JinkoSolar subsidiary
XtalPi Holdings signed a strategic cooperation agreement on AI plus automation high-throughput tandem solar cell R&D with a subsidiary of JinkoSolar. The two parties have established a joint venture company to jointly build the world's first fully closed-loop tandem cell intelligent manufacturing line integrating AI decision-making, robot execution and data feedback; the project is underway.
2026
XtalPi launches Genius Agent scientific AI agent
XtalPi (Jingta Technology) introduced its Genius Agent scientific AI agent at a dedicated promotion event held on August 11, 2026 at the Hetao Sci-Tech Innovation Center in Shenzhen, co-hosted with the Shenzhen Development and Reform Commission. The agent acts as a scheduling hub that connects digital hypotheses, professional predictions, physical verification and data feedback, turning XtalPi's internal algorithms, models and robotic lab capabilities into scientific intelligence infrastructure available to external research organizations.
2026
XtalPi launches XtalPi Science platform and Genius Agent matrix
In July 2026, XtalPi Holdings launched the XtalPi Science scientific intelligence platform and the Genius Agent scientific agent matrix. XtalPi Science is described as the world's first AI4S integrated platform combining large language models, scientific agents and large-scale automated robotic experiments, standardizing and platformizing the group's integrated research infrastructure into an on-demand, continuously extensible platform capability. The group also jointly initiated a Scientific Intelligence Open Ecosystem Alliance with 26 partners.
2022
Excelra and XtalPi announce GOSTAR data partnership
Excelra announced a partnership to provide ADMET datasets from its GOSTAR database to XtalPi, where the data will power XtalPi's predictive models.
2022
Leman Biotech and XtalPi establish strategic cooperation
Leman Biotech and XtalPi established a strategic cooperation to combine their respective capabilities in immunometabolism and cell therapy, AI, and computational chemistry, with plans to jointly develop an AI-based platform for immunometabolic regulator research.
2022
XtalPi and Chia Tai Tianqing announce drug-development partnership
XtalPi and Chia Tai Tianqing announced a strategic collaboration to jointly develop small-molecule drugs against difficult targets for cancer treatment. XtalPi will use its AI and computational chemistry platforms for compound generation, evaluation and optimization.
2022
Leman Biotech completes nearly RMB 100 million angel funding
Leman Biotech announced on January 18 that it had completed an angel funding round of nearly RMB 100 million, led by Tiantu Capital, with 5Y Capital and XtalPi also investing. The funding is intended to advance preclinical research and drug-candidate development, among other stated uses.
2020
XtalPi and Porton sign strategic collaboration
XtalPi and Porton signed a strategic collaboration to combine XtalPi's computational tools with Porton's experimental expertise for pharmaceutical research and development. Their U.S. subsidiary J-STAR also signed a sub-agreement to launch prediction-guided crystallization and solid-state research services for U.S. customers.